Clinical Trial Supply Chains: All You Need to Know

1. Clinical Trial Supply Chains: All You Need to Know

2. Introduction Clinical trial supply and logistics networks guarantee that study locations get the resources they require throughout the duration of the investigation. This enables patient visits to take place without being hampered by a lack of medications, supplies, or equipment. The COVID-19 epidemic put supply chains to the test. According to the Capgemini Research Institute’s Supply Chain Study, 74 percent of firms encountered delayed shipments/longer lead times, and 68 percent had items held up in ports or at borders, among other concerns. Let’s look at how you can make your organization’s research supply chain less sensitive to interruption.

3. What is a Supply Chain? A clinical trial supply logistics supply chain comprises everyone involved in the manufacturing and distribution networks. This includes the manufacturers and logistical companies that transport inputs from one step to the next. In addition to wholesalers, distributors and retailers need to ensure that items are available to consumers who desire them. A complex network of relationships shapes supply networks. These linkages influence not just the movement of resources from one location to another but also the incentives for businesses to spend on developing new products.

4. Recent Changes to Supply Chains Supply networks are more complicated, linked, and global than they have ever been. While the growing globalization of manufacturing has helped lower consumer costs in the United States, it also means that these supply chains are more vulnerable to disruption than ever before. As compared to previous years, organizations have observed a considerable increase in the number of supply chain interruptions since 2020.

5. Recent Changes to Supply Chains While COVID-19 was the primary cause of recent issues, additional events were part of recent big supply chain disruptions and may create future disruptions. Among these occurrences are: 1. Natural disasters 2. Cyberattacks 3. Transportation disruptions in both container shipping and trucking 4. Political instability and wars/conflicts

6. Recent Changes to Supply Chains It is becoming increasingly crucial to understand how to encourage rapid healing. It is also critical for businesses to have a strong incentive to spend in order to strengthen their supply and clinical trial logistics procurement networks. This is critical even if they may not be able to fully monetize the advantages of these investments owing to spillover effects to other sections of the networked system.

7. Problems with the Supply Chain Access to system functions is limited by user privileges, so only users who should have access to unblinded data in the IRT may view it. This information, like all of the activity captured by the IRT, may be transmitted to or integrated with another system. Controls are implemenThe frequency and magnitude of clinical trial supply chain logistics-related hazards increase as networks become increasingly integrated. Organizations have had to: 1. Assist in reducing the impact on production 2. They must reassess their supply chains to ensure product availability. 3. Examine manufacturing models. 4. Build a strategic inventory. .

8. Problems with the Supply Chain Companies also keep less inventory on hand as a result of outsourcing or transferring manufacturing elsewhere. Businesses that previously relied on purchasing items rapidly for a just-in-time production strategy have experienced not only delays but also the inability to supply goods at expected or contractual quantities. According to 25.3 percent of firms, this had a severe, serious, or catastrophic impact on their business.

9. Study Supply Chain Impact on Clinical Trials By July 2020, about 200 businesses had discontinued or postponed clinical studies because of the pandemic, with an estimated 80% of non-COVID-19 clinical trials paused or stopped.The COVID-19 pandemic has disrupted clinical trial supply networks, as it has disrupted other sectors of the global supply chain. As the epidemic progressed, delays persisted for months, and ongoing experiments were impeded as any inventory redundancies placed throughout their supply chain deteriorated. Persistent, high-level supply chain shortages spanned all sectors of health care, with 8 to 10 times as many commodities in short supply as before the pandemic.

10. Study Supply Chain Impact on Clinical Trials The clinical trial supply chain was further hampered by raw material shortages, governmental allotment of medical auxiliary supplies, and transportation difficulties. These interruptions have heightened the need of solid supplier and courier partnerships. Every delay, from equipment and supplies failing to arrive on schedule at a clinical facility to patients being unable to complete their appointments, causes an avalanche of consequences. These consequences might range from lower patient retention to longer time to market.

11. Making Clinical Trial Supply Chains Resilient It is critical for the management team to concentrate on reducing supply chain risk through supply chain resilience. The capacity of your firm to plan for, respond to, and recover from disruptions in a timely and cost-effective manner is referred to as supply chain resilience. Techniques to strengthen your clinical trial supply chain include: 1. Understanding the supply chain structure of your company 2. Purchasing backup capacity 3. Increasing the diversity of your supply base 4. Increasing your capacity to replace goods

12. Strengthening Your Study Supply Chain Developing ties with essential suppliers is critical. This, combined with allowing new suppliers in, product flexibility, contingency planning, and CTMS software logistics, can assist you in meeting your continuous demand for products and services. Octalsoft’s clinical software suite has prioritized supply chain resilience and taken the necessary steps to assure continuity and minimize interruptions. Book a demo with us now to learn more about how Octalsoft can help you power through clinical trial supply chain roadblocks.